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Introduction 
 Hypothalamic-pituitary dysfunction (HPD) often 
has a heterogeneous character, which 
determines the presence of various 
endocrinological comorbidities in one patient 
due to the anatomical proximity of the 
structures of the hypothalamic-pituitary region 
and the possibility of simultaneous damage of 
its neighboring areas. 
 Patients with chronic endocrine pathology should be educated about  
the characteristics of their disease and cautions in its treatment.  
 This clinical case illustrates the variety of clinical features in the patient 
with HPD and the consequences of insufficient education of the patient 
about the specific treatment cautions. 
  Physiology of hypothalamus and pituitary 
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  Posterior and anterior pituitary 
https://slideplaye
r.com/slide/1300
7574/79/images/
15/Posterior+%2
6+Anterior+Pituit
ary.jpg 
Diabetes insipidus 
Diabetes insipidus (DI) is defined as the 
passage of large volumes (>3 L/24 hr) of 
dilute urine (< 300 mOsm/kg).  
It is characterized by excessive urination ( 3-
20 L/day ) and extreme thirst as a result of: 
 inadequate output of the pituitary hormone 
ADH (antidiuretic hormone, also called 
arginine vasopressin [AVP]) 
or the lack of the normal response by the 
kidney to ADH.  
 
 
 
 
Diabetes [Greek] = to go 
through [describing excessive 
urination] 
Insipidus [Latin] = without taste 
https://www.sgagora.com.br/sg/wp-content/uploads/2018/05/diabetes-insipidus_22404_l-e1525360806527.jpg 
Facts about DI 
DI is a rare disease, with a prevalence of 1:25,000. 
The US rates of DI are much higher than the rest 
of the world – 1:6,666. 
Up to 30% of the cases of DI are idiopathic forms 
without identified cause. 
1 in 5 people who must undergo a cranial surgery 
will develop DI during their recovery period. 
The prognosis for patients with DI is generally 
excellent; DI-related mortality is rare in adults as 
long as water is available 
https://diabetesinsipidus.org/diabetes-
insipidus-statistics 
https://www.zipheal.com/wp-
content/uploads/2013/01/diabetes_insipi
dus_symptoms.jpg 
Types of DI 
Central DI - impaired synthesis, transport or osmoregulated 
secretion of vasopressin; 
Nephrogenic DI – due to resistance to ADH action in the kidney; 
Gestational DI - rare complication of pregnancy, usually developing 
in the third trimester and remitting spontaneously 4-6 weeks post-
partum.  
Primary polydipsia - a syndrome characterized by compulsive fluid 
intake with physiological inhibition of ADH secretion or 
dyspsogenic polydipsia with decreased sensitivity threshold of 
osmoreceptors. 
 
 
 
Causes of DI-1 
Central DI: 
  Genetic defects of ADH 
  synthesis and transport  
  Idiopathic (30% of the cases) 
  Head trauma or surgery 
  Tumors of the hypothalamic-
pituitary area 
  Vascular causes (Sheehan 
syndrome, thrombosis, 
hemorrhage, etc.) 
  Infections , autoimmune 
diseases, etc. 
 
 
Nephrogenic DI: 
  Genetic mutations (vasopressin 
V2 receptor gene, aquaporin 2 
gene) 
  Renal diseases (pyelonephritis, 
polycystic kidney disease) 
  Amyloidosis 
  Multiple myeloma 
  Sickle cell anemia 
  Medications such as lithium 
 
Causes of DI-2 
Primary polydipsia (PP) 
The pathogenesis of PP 
remains unexplored.  
Different theories include a 
dysfunction in the thirst 
mechanism, hippocampus 
involvement, stress-reducing 
behaviour, psychiatric 
disorders (schizophrenia, 
anxiety disorder, depression) 
Gestational DI 
 It is caused by excessive 
vasopressinase activity, an 
enzyme expressed by 
placental trophoblasts which 
metabolises AVP. 
 
Signs and symptoms of DI 
Polyuria (3 to 20 L) with large volumes of 
diluted urine  
Nocturia and related fatigue from interrupted 
sleep 
Polydipsia, especially a desire for cold fluids 
up to 20 L 
Marked dehydration, as evidenced by dry 
skin and mucous membranes, reduced 
sweating and salivation  
Low blood pressure 
Anorexia and epigastric fullness, weight loss 
 
 
 
 
https://i.pinimg.com/originals/1a/ac/76/1aac76579
9f13a3b7f3b51cf6568366a.jpg 
Diagnostics of DI 
A 24-hour urine collection for determination of urine volume 
(Zimnitskiy test) 
Serum electrolyte concentrations and glucose level 
Urinary specific gravity 
Simultaneous plasma and urinary osmolality 
Plasma ADH level 
Additional tests: 
Water deprivation (Miller-Moses) test to ensure adequate 
dehydration and maximal stimulation of ADH for diagnosis 
Pituitary studies, including magnetic resonance imaging (MRI) and 
measurement of circulating pituitary hormones other than ADH 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Treatment of central DI 
Dinamic monitoring of water balance (fluid intake and output) 
Urine osmolality, specific gravity of urine, blood electrolytes (Na, 
K, Mg, and P ) 
Hormone replacement with vasopressin or desmopressin, orally or 
intranasally. Orally in tablets initial dose of 0.1 mg 2-3 times a day 
orally 30-40 minutes before meals or 2 hours after meals. Average 
doses vary from 0.1 mg to 1.6 mg per day. Water consumption 
should be restricted 1 hour before and during desmopressin 
therapy. Side effects: hyponatriemia, headaches, face hyperemia, 
nausea, vomiting 
Rarely used - chlorpropamide, clofibrate, or carbamazepine (to 
stimulate secretion of ADH or increase release) 
 
 
Treatment of nephrogenic DI 
stopping any causative drug 
monitoring fluid balance, electrolyte levels, supplying I.V fluids 
Na restriction with thiazides (stimulates sodium and water 
reabsorption in PCT, that decreases water delivery to distal nephron 
limiting polyuria)  
Amiloride +/- thiazide : especially when Lithium exposure is the 
cause (amiloride limits lithium entry into tubular cells) 
others:  Indomethacin and ibuprofen, desmopressin (in those with 
receptor mutations high doses may be useful) 
Treatment of primary polydipsia (PP) 
 ingestion of a balanced diet, avoidance of drugs that may cause a 
dry mouth 
behavioral therapy such as disease education, relaxation training 
using biofeedback,, group therapy and etc. 
 in psychotic patients are used antipsychotic drugs and mood 
stabilizers such as olanzapine, lithium, risperidone, aripiprazole 
and clozapine, etc.  
Acute treatment of hyponatraemia in PP primarily consists of fluid 
restriction. In cases of profound and symptomatic hyponatraemia, 
a 3% saline infusion may be used 
Desmopressin and diuretics are contraindicated 
Obesity 
Obesity represents a state of abnormal or excessive storage of 
body fat that may impair health with BMI (body mass index) greater 
or equal 30 kg/m2 . 
 
BMI = kg/m2 
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European Guidelines for Obesity 
Management in Adults, 2015 
BMI measurement considerations 
Limitations to the use of BMI for 
diagnostic purposes are:  
the presence of edematous 
syndrome, for example, with 
decompensated heart failure, 
kidney disease;  
errors in the assessment of BMI 
are possible in athletes due to the 
significant development of 
muscle mass 
https://encrypted-
tbn0.gstatic.com/images?q=tbn%3AANd9GcTrK2jx75_fngQ2wphmhT3aGdbgf5D
rRIK-IOmbGbhc6-98bajZ&usqp=CAU 
 Fat distribution: gynoid vs android obesity  
Android: body fat around 
the trunk and upper body, in 
areas such as the abdomen, 
chest, shoulder and nape of 
the neck (apple shape).  
  Gynoid: body fat that forms 
around the hips, breasts 
and thighs (pear shape). 
 Useful tool for the differentiation of these types and fat distribution 
in obesity is the waist-to-hip ratio (WHR). It is the circumference of 
the waist divided by that of the hips.  
Morbid obesity 
Morbid obesity - a serious health condition 
that results from an excessive body mass: 
  with a body mass index (BMI) > 40 kg/m²,  
a BMI > 35 kg/m² with at least one serious 
obesity-related condition such as type 2 
diabetes mellitus, arterial hypertension, etc.,  
Weight of the patient is more than 100 
pounds over ideal body weight (IBW). 
https://i.imgflip.com/1sfuoi.jpg 
Types of obesity 
Obesity is divided to: 
Primary (alimentary constitutional): gynoid and android. 
Primary obesity is associated with an excessive caloric intake, 
decreased energy expenditure and/or a combination of the two. 
Secondary obesity due to another diseases: 
1. With an identified genetic defect (i.e. Down syndrome, etc.) 
2. Cerebral (adipozogenital dystrophy, brain tumors, infectious 
diseases, disseminated systemic lesions) 
3. Endocrine (hypothyroid, hypovarian, diseases of the 
hypothalamic-pituitary system, adrenal gland diseases); 
4. Iatrogenic (due to drug intake: steroid treatment, etc.) 
 
Some types of secondary obesity 
Cushing disease Down syndrome Hypothyroidism 
https://www.degruyter.com/view/j/jpem.ahead-of-print/jpem-2013-0070/graphic/jpem-2013-0070_fig1.jpg , http://www.scielo.org.za/img/revistas/samj/v106n7/13t3.jpg  
Diagnostics of obesity 
Fasting blood glucose 
Serum lipid profile (total, HDL and LDL cholesterol, triglycerides)  
Uric acid 
Thyroid investigation (thyroid-stimulating hormone (TSH) level, T3, T4, 
anti-TPO, thyroid ultrasound) 
Cardiovascular assessment, if indicated  
Endocrine evaluation if Cushing’s syndrome or hypothalamic disease 
suspected 
Liver investigation (Liver function tests, ultrasound, biopsy) if abnormal 
liver function tests suggest NAFLD or other liver pathology 
Sleep laboratory investigation for sleep apnea. 
 
Management of obesity 
 European Guidelines for Obesity Management in Adults,  2015 
Management of comorbidities: 
– management of dyslipidemia, 
– glycemic control in type 2 DM, 
– normalizing BP in hypertension, 
– management of pulmonary 
disorders (sleep apnoea syndrome), 
–pain control and mobility needs in 
osteoarthritis, 
– management of psychosocial 
disturbances (affective disorders, 
eating disorders, low self esteem and 
body image disturbance). 
Our patient 
Name: R. T. 
  Sex: Male 
  Age: 24 Years (1995) 
  Location: Kharkiv 
  Occupation: Paramedic 
  Level of disability: disability from childhood (lllrd degree) 
 
 
Complaints 
frequent painless urination with the release of a large volume of 
colorless urine (urinates every 2-3 hours, diuresis 8-10 l / day with a 
predominance of night diuresis);  
thirst (drinks 8-10 l of fluid per day);  
weight gain (over the past year has gained 10 kg);  
Also complains of periodically occurring diffuse headaches of a 
expanding nature, dyspnea of mixed character during physical 
exertion (fast running, climbing to the 4th-5th floor). 
Anamnesis of present  illness -1 
Thirst and urination with passage of large volumes of dilute urine 
first appeared at age of 3,5 years (was on breastfeeding till 3 years). 
Was diagnosed with central diabetes insipidus, replacement 
therapy (desmopressin) was prescribed, against which the patient's 
condition improved (thirst, diuresis decreased to 3-4 l/day).  
Since 4 years the patient has been gaining weight progressively. 
Patient has planned inpatient treatment in the endocrinology 
department annually. The last 5 years the patient took 
desmopressin unsystematically and did not adhere to the water 
regimen restrictions during drug therapy. When using 
desmopressin, he also noted the occurrence of a headache, 
accompanied by nausea.  
 
Anamnesis of present  illness -2 
 In November 2019, the patient stopped treatment, because, in his 
opinion, “desmopressin increased his weight and caused 
headaches”.  After this, the patient's condition worsened, diuresis 
and thirst increased significantly. He referred to endocrinologist for 
further investigation and correction of therapy. 
 
Anamnesis of life 
Patient is working as a paramedic;  
Married, has a son; 
Denies alcohol abuse, smoking (stopped smoking in 2018, before 
had been smoking since 13 years old – 1 pack per day).  
Postponed diseases: upper respiratory viral infections (URVI), 
postponed operations: denies.  
Tuberculosis, viral hepatitis, HIV, diabetes mellitus, peptic ulcer, 
allergic reactions denies. 
Hereditary history is not burdened. 
Disability from childhood - lllrd degree 
 
Objective examination-1 
General condition of the patient is satisfactory. 
Height 1.84m, weight 155kg, BMI-45.8 kg/m2, waist circumference – 
146cm, hip circumference – 145cm, waist-to-hip ratio -1.1. T=36,7 C. 
Skin is clean, turgor, moistness is preserved; there are pink striae in 
the chest area, pale striae in the shoulder area; visible mucous 
membranes are clean, moist.  
Subcutaneous adipose tissue - developed excessively, more 
pronounced in the abdomen, chest, back. There is gynecomastia, 
buffalo hump. Lymphatic nodes - not palpable. No edemas. 
Musculo-sceletal system – without pathological changes. 
Objective examination-2 
Thyroid gland is not enlarged.  
Lungs: resonance percussion sound, vesicular breathing over both 
lungs fields, RR -18/min.  
Heart borders on percussion are not enlarged, heart tones are clear, 
muffled, rhythmic; BP dex – 140/95, BP sin – 140/92, HR=pulse - 100 
bpm, rhythmic.   
Abdomen is painless on palpation in all regions. Liver is not 
enlarged ( liver size according to Kurlov: 7-8-9 cm), the spleen is not 
palpable.  
Tapping sign - negative on both sides. Urination - free, painless, 
frequent, voluminous (up to 20 times per day).  
 
Objective status 
 Abdominal obesity is present, gynecomastia, purple striae (black arrows) 
Plan of survey 
 Full blood count, urinalysis 
 Biochemical panel (FPG, OGTT,  lipid profile, CRP, electrolytes, LFT, KFT); 
 Insulin level, HOMA index;  
 thyroid function tests (T3, T4, TSH, anti-TPO ab), prolactin, cortizol; 
 Serological panel (viral hepatitis B, C tests); 
 ADH in blood, brain contrast MRI – refused to do tests due to financial 
issues 
 ECG, EchoCG; 
 Brain CT, EEG, REG; 
 Ultrasound of kidneys, abdominal organs, thyroid gland, breast glands; 
 Consultation of endocrinologist, cardiologist, neurologist 
Full blood count 
Options Results Normal range 
Hemoglobin, g/L 145 130,0 – 160,0 
Erythrocytes × 𝟏𝟎𝟏𝟐/l 4,72 3,7-4,7 
Color index  0,92 0,85 – 1,15 
Leukocytes × 𝟏𝟎𝟗/L 8,3 4,0 – 9,0 
ESR, mm/h 5 2-15 
Stab neutrophils, % 1 1-6 
Segmented neutrophils, % 54 47-72 
Eosinophils, % 2 0,5-5,0 
Basophils, % 0 1-1,0 
Lymphocytes, % 36 19-37 
Monocytes, % 7 3-11 
Conclusion: all parameters within the normal range 
Urine analysis 
Options Results Normal range 
Amount, ml 60  
Specific gravity   1,003 1,012-1,024 
pH alkaline 5,0-7,0 
Color colorless yellow 
Transparency transparent transparent 
Protein, g / l not detected to 0.033 
Glucose  not detected absent 
Leucocytes, cells/hpf 1-2 0-6 
Epithelium, cells/hpf 0 absent 
Bacteria  Not detected absent 
Conclusion: decreased urine specific gravity  
 Zimnitskiy test 
Options Results 
Diuresis during 24 hours 6.00-9.00 a.m.  1000 ml 
9.00 -12.00 1300 ml 
12.00 - 3.00 p.m. 1750 ml 
3.00 - 6.00 p.m. 2050 ml 
6.00 – 9.00 p.m. 2600 ml 
9.00 – 0.00 1900 ml 
0.00 – 3.00 a.m. 2000 ml 
3.00 – 6.00 a.m. 800 ml 
Total diuresis, ml 13400 ml Day diuresis  
6100 ml 
Night diuresis 
7300 ml 
Min specific gravity 1000 Max specific gravity 1003 
Conclusion: decreased urine specific gravity during 24 hours, increased diuresis, nocturia 
Biochemical panel () 
Options Results Normal range 
Total billirubin, mkmol/l 9,0 5-21 
Direct billirubin, mkmol/l 3,0 2,2-5,3 
Undirect billirubin, mkmol/l 6,0 6,5-15,4 
ALT, U/l 101,9 <40 (men) 
AST, U/l 37,1 <38 (men) 
Urea, mmol/l 4,8 1,7-8,3 
Creatinine, mkmol/l 100 62-123 
CRP, mg/l negative <5  
Conclusion: increased level of ALT 
Biochemical panel 
Options Results Normal range 
Serum Ca, mmol/l 2,2 2,2-2,5 
Serum Fe, mkmol/l 18,4 9,0-29 
Serum P, mmol/l 1,0 0,8-1,4 
Serum K, mmol/ml 4,52 3,5-5,0 
Serum Cl, mmol/l 100 98-106 
Serum Na, mmol/l 142 136-145 
Alkaline phosphatase, 
nmol/l 
2200 1200-6300 
Serum osmolality, mosm/kg 303,06 
Urine osmolality, mosm/kg 99,90 
Conclusion: increased serum osmolality, decreased urine osmolarity 
Biochemical panel - lipid profile 
Options Results Normal range 
Total cholesterol, mmol/l 6,69 < 5,2 (5,2-6,2 borderline level) 
Very low-density lipoprotein 
cholesterol (VLDL-C), mmol/l 
2,86 0,26-1,0 
Low-density lipoprotein 
cholesterol (LDL-С) ), mmol/l 
2,93 <4,12 
High-density lipoprotein 
cholesterol (HDL-C) ), mmol/l 
1,28 >0,9 
Triglycerides), mmol/l 6,29 <2,3 
Atherogenic coefficient 6,43 2,5-3,0 
Conclusion: increased level of total cholesterol, VLDL, triglycerides, atherogenic  
                      coefficient 
  Biochemical panel 
Options Results Normal range 
FPG (fasting plasma glucose), 
mmol/l 
5,22 4,0-6,1 
OGTT (oral glucose tolerance 
test), mmol/l 
5,22 – 7,1 – 4,2 Fasting - 4,0-6,1 
After 2 hours - <7,8 
Insulin,  30,99 2,6-24,9 
HOMA index 7,19 <3,0 
Conclusion: increased level of insulin, HOMA index   
  Biochemical panel 
Options Results Normal range 
Prolactin, ng/ml 15,5 2,5-17,0 
Cortisol, nmol/l 475 138-690 
TSH, mcME/ml 0,946 0,27-4,2 
Free T3, pg/ml 3,15 2,0-4,4  
Free T4, ng/dl 0,975 0,89-1,76  
Anti-TPO antibodies, U/ml 16,9 <30,0 
Conclusion: all parameters within the normal range 
  Serological panel 
Options Results Normal range 
Hepatitis B virus, HBsAG 0,031  <0,192 
Hepatitis C virus, anti-HCV total 0,034 <0,222 
Conclusion: all parameters within the normal range 
Instrumental investigations-1 
X-ray of the skull: signs of intracranial hypertension, turkish saddle 
without pathological changes. 
EEG: moderate diffuse changes of an irritative nature. 
REG: changes of the dystonic type. Obstructed venous outflow. 
CT scan of the brain: convexital subarachnoid spaces without 
pathological features. Slightly dilated lateral ventricles. Middle 
structures are not biased. In the anteroposterior area on the right 
there is an arachnoid cyst up to 11.1 x 8.4 x 20 mm. Pathological 
foci in the substance of the brain were not identified. 
EchoCG: chambers of the heart are not enlarged, myocardial 
contractility is satisfactory, ejection fraction – 62%. 
Instrumental investigations-2 
Ultrasound of the thyroid gland. The thyroid gland is not enlarged, 
located in a typical place, without pathological changes.  
Ultrasound of the kidneys. The kidneys are located typically, of 
normal shape and size. The parenchyma is not thinned, 
pyelocaliceal system is not expanded, no pathological changes.  
Ultrasound of the breast glands: the structure of the breast glands 
is of a fatty type. No areas of glandular hyperplasia were detected. 
The ducts are not expanded. Pathological masses in the structure 
of the breast glands were not detected. 
Ultrasound od the abdominal organs: liver is not enlarged, signs of 
adiposis of the liver. Spleen, pancreas, gall bladder without 
pathological changes.  
 
 
ECG 
Conclusion:  
sinus tachycardia, HR-100, 
Left axis deviation  
(aF QRS = -30), left anterior 
bundle brunch block, 
Incomplete RBBB, 
reduction of repolarization 
processes along the 
anterior-lateral wall of the 
left ventricle  
Consultations of specialists-1 
Consultation of endocrinologist: Hypothalamic-pituitary 
dysfunction with metabolic and endocrine disorders in the form of 
central diabetes insipidus of moderate severity, obesity of ІІІ 
degree, arterial hypertension of 1st degree, I stage; cerebrospinal 
venous hypertension, striatal syndrome. Non-alcoholic 
steatohepatosis. 
Recommended: Diet with restriction of satured fat, fast absorbed 
carbohydrates; food intake 5-6 times per day in small portions.  
Desmopressin (uropres) in a starting dose – 5 mcg intranasally with 
subsequent uptitrating the dose; decrease fluid intake 1 hour before 
and during use of desmopressin. 
Consultation of neurologist: discirculatory-dysmetabolic 
encephalopathy ІІ stage with cerebrospinal venous hypertension.  
 
 
 
Consultations of specialists-2 
Consultation of cardiologist: arterial hypertension of І stage, 1 
grade, HF0, high cardiovascular risk. Recommended: lifestyle 
modification (diet with restriction of salt, saturated fat; physical 
activity), bisoprolol – 5mg once daily under control of HR, BP. 
Administration of statins is recommended after normalization of 
LFT levels. 
Consult of gastroenterologist: Nonalcoholic hepatic steatosis. 
Recommended: diet, ademetionin 500 mg twice daily 1 month with 
subsequent control of LFT.     
Differential diagnosis of DI types 
Criteria Central DI Nephrogenic DI Dipsogenic DI Our patient 
Urine specific 
gravity 
<1005 <1005 <1010 1000-1003 
Plasma 
osmolality 
>290 >290 <280 
 
303,3 
Urine osmolality <200 <200 <300 99,90 
Sodium in blood N 142 
ADH in blood Test wasn’t 
performed 
Desmopressin 
treatment effect 
+ - ++ + (diuresis 
decreased to 3-4 
l/day) 
Diagnosis 
Diagnosis: Hypothalamic-pituitary dysfunction with metabolic and 
endocrine disorders in the form of central diabetes insipidus of 
moderate severity, obesity of ІІІ degree, arterial hypertension of І 
stage, 1 grade, HF0, high cardiovascular risk; striatal syndrome. 
Discirculatory-dysmetabolic encephalopathy ІІ st. with 
cerebrospinal venous hypertension. Arachnoid cyst of the right 
frontal posterior region. Nonalcoholic hepatic steatosis. 
 
Treatment recommendations -1 
Lifestyle recommendations: 
Diet with restriction of satured fat, fast absorbed carbohydrates, 
salt; food intake 5-6 times per day in small portions.  
Physical activity (FA) of a dynamic nature, moderate intensity, 
starting with minimal loads with a gradual increase in the intensity. 
Treatment recommendation -2 
Desmopressin (uropres) in a starting dose – 5 mcg intranasally 
with subsequent uptitrating the dose; decrease fluid intake 1 hour 
before and during use of desmopressin. 
Bisoprolol – 5mg once daily under control of HR, BP.  
Ademetionin 500 mg twice daily 1 month with subsequent control 
of LFT. 
Administration of statins is recommended after normalization of 
LFT levels. 
Dynamic observation of endocrinologist, neurologist, 
neurosurgeon, cardiologist, gastroenterologist. 
 
 
Conclusion 
HPD is accompanied by a variety of clinical manifestations, and the 
components of HPD form a vicious circle, exacerbating each other. 
HPD in this patient manifested as central diabetes insipidus in 
combination with metabolic syndrome (morbid obesity, dyslipidemia, 
arterial hypertension, insulin resistance). 
The patient's lack of awareness of the specific features of diabetes 
insipidus treatment led to the appearance of the side effects, 
worsening of the general condition and self-cancellation of 
desmopressin. 
Thus, informing and education of patients about the characteristics 
of their disease and cautions in drug intake is important for the 
achieving of effectiveness in the endocrine pathology treatment. 
 
Thank you for your attention! 
Any questions? 
